Document Detail

Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization.
MedLine Citation:
PMID:  21691137     Owner:  NLM     Status:  Publisher    
Purpose: Treatment of neovascularization in ocular diseases with vascular endothelial growth factor (VEGF) inhibition shows promising results. SU5416 is a low-molecular-weight tyrosine kinase inhibitor. It selectively inhibits the membrane-bound tyrosine kinase activity of VEGF-2 receptor (Flk-1/KDR) and blocks the intracellular signaling process. The aim of this study was to evaluate the effect of SU5416 on corneal neovascularization. Methods: Corneas were cauterized with silver nitrate/potassium nitrate sticks in 20 eyes of 20 BALB/C mice. In the study group (n = 10), SU5416 (25 mg/kg) dissolved in dimethyl sulfoxide was given as an intraperitoneal injection in a single daily dose for 7 days. The other group of 10 mice given intraperitoneal dimethyl sulfoxide alone served as a control group. After 7 days, corneal neovascularization was evaluated using photographs captured by fluorescein angiography. Colored photographs were taken by a biomicroscope with a digital camera. Data were expressed as mean neovascular length and mean number of new vessels for each animal. The values were computed and compared between the groups. Results: The mean burn stimulus intensities were not different between the groups. In the study group, the mean length of the vessels and the mean number of vessels were 0.49 ± 0.05 and 11.20 ± 1.69 mm, respectively. In the control group, the mean length of the vessels and the mean number of the vessels were 0.89 ± 0.11 and 17.80 ± 1.03 mm, respectively. There is a statistically significant difference in the mean length and the mean number of new vessels between the study and control groups (p < 0.001). Conclusion: Selective inhibition of VEGFR-2 (Flk-1/KDR) tyrosine kinase with SU5416 was shown to have an inhibitory effect on corneal neovascularization in this animal model. VEGFR-2 (Flk-1/KDR) tyrosine kinase inhibition may represent a different pathway for treatment of the neovascularization process in ocular pathologies. Fluorescein angiography photographs of new vessels on the cornea may provide a better evaluation of neovascularization than colored images in animal models.
Uğurcan Keskin; Yüksel Totan; Remzi Karadağ; Mesut Erdurmuş; Bahri Aydın
Related Documents :
6774337 - Sequential folding of a bifunctional allosteric protein.
15659667 - Characterization of the roka and hexa broad-substrate-specificity hexokinases from bact...
1511997 - Hereditary nonspherocytic hemolytic anemia due to pyruvate kinase deficiency: a prevale...
8480077 - Theophylline increases pyridoxal kinase activity independently from vitamin b6 nutritio...
22199287 - Cytoskeleton network and cellular migration modulated by nuclear-localized receptor tyr...
210627 - Polymeric structure of a cyclic adenosine 3', 5',-monophosphate dependent protein kinas...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-6-21
Journal Detail:
Title:  Ophthalmic research     Volume:  47     ISSN:  1423-0259     ISO Abbreviation:  -     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-6-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0267442     Medline TA:  Ophthalmic Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  13-18     Citation Subset:  -    
Copyright Information:
Copyright © 2011 S. Karger AG, Basel.
Department of Ophthalmology, Fatih University Medical School, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vitreous Vascular Endothelial Growth Factor Concentrations in Proliferative Diabetic Retinopathy ver...
Next Document:  Influence of Hyperbaric Oxygen Therapy on Central Corneal Thickness.